Association of Adiponectin Receptor (Adipo-R1/-R2) Expression and Colorectal Cancer

  • Ayyildiz, Talat (Department of Gastroenterology, Medical Faculty, Ondokuz Mayis University) ;
  • Dolar, Enver (Department of Gastroenterology, Medical Faculty, Uludag University) ;
  • Ugras, Nesrin (Department of Pathology, Medical Faculty, Uludag University) ;
  • Adim, Saduman Balaban (Department of Pathology, Medical Faculty, Uludag University) ;
  • Yerci, Omer (Department of Pathology, Medical Faculty, Uludag University)
  • Published : 2014.11.28


Introduction: Human adiponectin (ApN) is a 30 kDa glycoprotein of 244-amino acids which is extensively produced by adipocytes. ApN acts via two receptors, namely adiponectin receptor-1 (Adipo-R1) and adiponectin receptor-2 (Adipo-R2). Studies have shown the presence of Adipo-R1 and Adipo-R2 expression immunohistochemically in human colorectal cancers (CRCs). However, only a few studies exist which investigated effects of adiponectin receptor expression on CRC characteristics. Objectives: In the present study, we aimed to explore Adipo-R1/-R2 expression in human colorectal cancers and any association with clinicopathological characteristics and survival. Materials and Methods: The study enrolled 58 colorectal cancer patients with tumor resection and a control group of 30 subjects with normal colon mucosa. Results: Positivity for Adipo-R1/-R2 expression was significantly more common in the control group in comparison to the patient group (both p<0.001). There was no significant association between Adipo-R1/-R2 expression and clinicopathological characteristics including age, sex tumor location, pTNM stage, Duke's stage, metastasis, histological differentiation, perineural invasion, venous invasion sex, lymphatic invasion, cancer-related mortality, tumor size and recurrence. Adipo- R1/-R2 positivity was also not significantly linked to progression-free or overall survival [p values (0.871, 0.758) and (0.274, 0.232), respectively]. Conclusions: Although significantly reduced Adipo-R1/-R2 expression was found in colorectal cancer patients, it had no influence on survival.


  1. Ayyildiz T, Dolar E, Ugras N, et al (2014). Lack of any prognostic relationship between adiponectin receptor (Adipo R1/R2) expression for early/advanced stage gastric cancer. Asian Pac J Cancer Prev, 15, 4711-16.
  2. Barresi V, Tuccari G, Barresi G (2009a). Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density. Pathology, 41, 533-8.
  3. Barresi V, Grosso M, Giuffre G, Tuccari G, Barresi G (2009b). The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clin Pathol, 62, 705-9.
  4. Brakenhielm E, Veitonmaki N, Cao R, et al (2004). Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA, 101, 2476-81
  5. Byeon JS, Jeong JY, Kim MJ, et al (2010). Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer, 127, 2758-67.
  6. Chen MW, Ye S, Zhao LL, et al (2012). Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol, 29, 3129-35.
  7. Cnop M, Havel PJ, Utzschneider KM, et al (2003). Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 46, 459-69.
  8. Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013). Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci, 14, 16365-85.
  9. Dal Maso L, Augustin LS, Karalis A, et al (2004). Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab, 89, 1160-3.
  10. Dalamaga M, Diakopoulos KN, Mantzoros CS (2012). The role of adiponectin in cancer: a review of current evidence. Endocr Rev, 33, 547-94.
  11. Dancey JE (2002). Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am, 16, 1101-14 .
  12. Fukumoto J, Otake T, Tajima O, et al (2008). Adiponectin and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci, 99, 781-6.
  13. Goldfine AB, Kahn CR (2003). Adiponectin: linking the fat cell to insulin sensitivity. Lancet, 362, 1431-2.
  14. Gonullu G, Kahraman H, Bedir A, et al (2010). Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis, 25, 205-12.
  15. Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev, 13, 395-8.
  16. Ho GY, Wang T, Gunter MJ, et al (2012). Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res, 72, 3029-37.
  17. Huang S, Houghton PJ (2003). Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol, 3, 371-77.
  18. Ishikawa M, Kitayama J, Kazama S, et al (2005). Plasma adiponectin and gastric cancer. Clin Cancer Res, 11, 466-72.
  19. Joshi RK, Lee SA (2014). Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev, 15, 397-405.
  20. Kadowaki T, Yamauchi T, Kubota N, et al (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 116, 1784-92.
  21. Kamada Y, Matsumoto H, Tamura S, et al (2007). Hypoadiponectinemia accelerates hepatic tumor formation in nonalcoholic steatohepatitis mouse model. J Hepatol, 47, 556-64.
  22. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G (2002). Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care, 25, 971- 6.
  23. Kelesidis I, Kelesidis T, Mantzoros CS (2006). Adiponectin and cancer: a systematic review. Br J Cancer. 94, 1221-5.
  24. Kojima S, Kojima S, Maruyoshi H, et al (2011). Hypercholesterolemia and hypoadiponectinemia are associated with necrotic core-rich coronary plaque. Int J Cardiol, 147, 371-6.
  25. Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E (2009). Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis, 24, 275-81.
  26. Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P (2006). Serum adiponectin is not associated with risk of CRC. Cancer Epidemiol Biomarkers Prev, 15, 401-2.
  27. Mantzoros C, Petridou E, Dessypris N, et al (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab, 89,1102-7.
  28. Matsuzawa Y, Shimomura I, Kihara S, et al (2003). Importance of adipocytokines in obesity-related diseases. Horm Res, 3, 56-9.
  29. Michalakis K, Williams CJ, Mitsiades N, et al (2007). Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev, 16, 308-13.
  30. Moore LL, Bradlee ML, Singer MR, et al (2004). BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord, 28, 559-67.
  31. Murphy TK, Calle EE, Rodriguez C et al (2000). Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol, 152, 847-54.
  32. Oldham S, Hafen E (2003). Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol, 13, 79-85.
  33. Otake S, Takeda H, Suzuki Y, et al (2005). Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res, 11, 3642-6.
  34. Ouchi N, Kihara S, Arita Y, et al (1999). Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100, 2473-6.
  35. Ouchi N, Kihara S, Arita Y, et al (2001). Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 103, 1057-63.
  36. Philp AJ, Campbell IG, Leet C, et al (2001). The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res, 61, 7426-29.
  37. Rodrigues VS, Milanski M, Fagundes JJ, et al (2012). Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease. Clin Exp Immuno, 170, 358-64.
  38. Saxena A, Baliga MS, Ponemone V, et al (2013). Mucus and adiponectin deficiency: role in chronic inflammation-induced colon cancer. Int J Colorectal Dis, 28,1267-79
  39. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin , 62:220-41.
  40. Vogt PK (2001). PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med, 7, 482-4.
  41. Wei EK, Giovannucci E, Fuchs CS, Willet WC, Mantzoros CS (2005). Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst, 97, 1688-94.
  42. Williams CJ, Mitsiades N, Sozopoulos E, et al (2008). Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer, 15, 289-99.
  43. Wolpin BM, Mayer RJ (2008). Systemic treatment of colorectal cancer. Gastroenterol, 134, 1296-10.
  44. Yamauchi T, Kamon J, Ito Y, et al (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423, 762-9.
  45. Yang WS, Lee WJ, Funahashi T, et al (2002). Plasma adiponectin levels in overweight and obese Asians. Obes Res, 10, 1104-10.
  46. Yoneda K, Tomimoto A, Endo H, et al (2008). Expression of adiponectin receptors, Adipo-R1 and Adipo-R2, in normal colon epithelium and colon cancer tissue. Oncol Rep, 20, 479-83.

Cited by

  1. Adipo-R1 and Adipo-R2 Expression in Colorectal Adenomas and Carcinomas vol.16, pp.1, 2015,
  2. Associations of Serum Isoflavone, Adiponectin and Insulin Levels with Risk for Epithelial Ovarian Cancer: Results of a Case-control Study vol.16, pp.12, 2015,
  3. Adiponectin and colorectal cancer vol.47, pp.2, 2017,
  4. Bone Marrow Adipocyte: An Intimate Partner With Tumor Cells in Bone Metastasis vol.9, pp.1664-2392, 2018,
  5. Adiponectin as Link Factor between Adipose Tissue and Cancer vol.20, pp.4, 2019,